-
1
-
-
0034658676
-
Diagnosis and treatment of atrophic vaginitis
-
Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 2000;61:3090-3096.
-
(2000)
Am Fam Physician
, vol.61
, pp. 3090-3096
-
-
Bachmann, G.A.1
Nevadunsky, N.S.2
-
3
-
-
68349155731
-
Prevalence and impact of vaginal symptoms among postmenopausal women
-
Santoro N, Komi J. Prevalence and impact of vaginal symptoms among postmenopausal women. J Sex Med 2009;6:2133-2142.
-
(2009)
J Sex Med
, vol.6
, pp. 2133-2142
-
-
Santoro, N.1
Komi, J.2
-
4
-
-
67649365524
-
Postmenopausal women's attitudes: Vulvovaginal atrophy and its symptoms [abstract LB-10]
-
Simon JA, Komi J. Postmenopausal women's attitudes: vulvovaginal atrophy and its symptoms [abstract LB-10]. Menopause 2007;14:1107.
-
(2007)
Menopause
, vol.14
, pp. 1107
-
-
Simon, J.A.1
Komi, J.2
-
5
-
-
0037125379
-
Risk and benefits of estrogen plus progestin in healthy postmenopausal women
-
Writing Group for the Women's Health Initiative Investigators
-
Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-333.
-
(2002)
JAMA
, vol.288
, pp. 321-333
-
-
-
6
-
-
51449124264
-
Estrogen and progestogen use in postmenopausal women: July 2008 position statement of the North American Menopause Society
-
The North American Menopause Society
-
The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008;15:584-602.
-
(2008)
Menopause
, vol.15
, pp. 584-602
-
-
-
7
-
-
69649108864
-
The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of the North American Menopause Society
-
The North American Menopause Society
-
The North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007;14:355-369.
-
Menopause
, vol.2007
, Issue.14
, pp. 355-369
-
-
-
9
-
-
64049083020
-
Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmeno-pausal women
-
Labrie F, Cusan L, Gomez JL, et al. Effect of one-week treatment with vaginal estrogen preparations on serum estrogen levels in postmeno-pausal women. Menopause 2009;16:30-36.
-
(2009)
Menopause
, vol.16
, pp. 30-36
-
-
Labrie, F.1
Cusan, L.2
Gomez, J.L.3
-
10
-
-
37549023420
-
Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: A randomized controlled trial
-
Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol 2008;111:67-76.
-
(2008)
Obstet Gynecol
, vol.111
, pp. 67-76
-
-
Bachmann, G.1
Lobo, R.A.2
Gut, R.3
Nachtigall, L.4
Notelovitz, M.5
-
11
-
-
58149280795
-
Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet
-
Erratum in: Obstet Gynecol 2008;112, 1392
-
Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008;112:1053-1060. Erratum in: Obstet Gynecol 2008;112:1392.
-
(2008)
Obstet Gynecol
, vol.112
, pp. 1053-1060
-
-
Simon, J.1
Nachtigall, L.2
Gut, R.3
Lang, E.4
Archer, D.F.5
Utian, W.6
-
12
-
-
64049105055
-
Vulvovaginal atrophy: New and upcoming approaches
-
Simon JA. Vulvovaginal atrophy: new and upcoming approaches. Menopause 2009;16:5-7.
-
(2009)
Menopause
, vol.16
, pp. 5-7
-
-
Simon, J.A.1
-
13
-
-
17744368482
-
Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats
-
Qu Q, Zheng H, Dahllund J, et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology 2000;141:809-820.
-
(2000)
Endocrinology
, vol.141
, pp. 809-820
-
-
Qu, Q.1
Zheng, H.2
Dahllund, J.3
-
14
-
-
0034907007
-
In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer
-
Taras TL, Wurz GT, DeGregorio MW. In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer. J Steroid Biochem Mol Biol 2001;77:271-279.
-
(2001)
J Steroid Biochem Mol Biol
, vol.77
, pp. 271-279
-
-
Taras, T.L.1
Wurz, G.T.2
Degregorio, M.W.3
-
15
-
-
27744590563
-
Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice
-
Wurz GT, Read KC, Marchisano-Karpman C, et al. Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice. J Steroid Biochem Mol Biol 2005;97:230-240.
-
(2005)
J Steroid Biochem Mol Biol
, vol.97
, pp. 230-240
-
-
Wurz, G.T.1
Read, K.C.2
Marchisano-Karpman, C.3
-
16
-
-
34447637387
-
Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ
-
Namba R, Young LJ, Maglione JE, et al. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ. Breast Cancer Res 2005;7: 881-889.
-
(2005)
Breast Cancer Res
, vol.7
, pp. 881-889
-
-
Namba, R.1
Young, L.J.2
Maglione, J.E.3
-
17
-
-
0642306447
-
Effects of ospemifene, a novel SERM, on vascular markers and function in healthy postmeno-pausal women
-
Ylikorkala O, Cacciatore B, Halonen K, et al. Effects of ospemifene, a novel SERM, on vascular markers and function in healthy postmeno-pausal women. Menopause 2003;10:440-447.
-
(2003)
Menopause
, vol.10
, pp. 440-447
-
-
Ylikorkala, O.1
Cacciatore, B.2
Halonen, K.3
-
18
-
-
0642367765
-
Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and on quality of life in postmeno-pausal women: A double-blind randomized trial
-
Rutanen E-M, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and on quality of life in postmeno-pausal women: a double-blind randomized trial. Menopause 2003;10: 433-439.
-
(2003)
Menopause
, vol.10
, pp. 433-439
-
-
Rutanen, E.-M.1
Heikkinen, J.2
Halonen, K.3
Komi, J.4
Lammintausta, R.5
Ylikorkala, O.6
-
19
-
-
1542267719
-
Effects of ospemifene, a novel SERM, on biological markers of bone turnover in healthy postmenopausal women
-
Komi J, Heikkinen J, Rutanen EM, Halonen K, Lammintausta R, Ylikorkala O. Effects of ospemifene, a novel SERM, on biological markers of bone turnover in healthy postmenopausal women. Gynecol Endocrinol 2004;18:1-7.
-
(2004)
Gynecol Endocrinol
, vol.18
, pp. 1-7
-
-
Komi, J.1
Heikkinen, J.2
Rutanen, E.M.3
Halonen, K.4
Lammintausta, R.5
Ylikorkala, O.6
-
20
-
-
20144388972
-
Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract and tolerability in postmenopausal women
-
Komi J, Lankinen KS, Härkönen P, et al. Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract and tolerability in postmenopausal women. Menopause 2005;12:202-209.
-
(2005)
Menopause
, vol.12
, pp. 202-209
-
-
Komi, J.1
Lankinen, K.S.2
Härkönen, P.3
-
21
-
-
33745603721
-
Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women
-
Komi J, Lankinen KS, DeGregorio M, et al. Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J Bone Miner Metab 2006;24:314-318.
-
(2006)
J Bone Miner Metab
, vol.24
, pp. 314-318
-
-
Komi, J.1
Lankinen, K.S.2
Degregorio, M.3
-
22
-
-
77952253619
-
TM (ospemifene) effectively treats vulvovaginal atrophy in postmenopausal women: Results from a pivotal phase 3 study [abstract P2-513]
-
June San Francisco, CA
-
TM (ospemifene), effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study [abstract P2-513]. Paper presented at: Endocrine Society's Annual Meeting; June 15-18, 2008; San Francisco, CA.
-
(2008)
Paper Presented At: Endocrine Society's Annual Meeting
, pp. 15-18
-
-
Bachmann, G.A.1
Komi, J.2
Hanley, R.3
-
23
-
-
68349161052
-
Ospemifene, a new SERM, improves the symptoms of vaginal dryness and dyspareunia in postmenopausal women: Results from a pivotal phase 3 study [abstract OR6-03]
-
Simon JA, Komi J. Ospemifene, a new SERM, improves the symptoms of vaginal dryness and dyspareunia in postmenopausal women: results from a pivotal phase 3 study [abstract OR6-03]. Climacteric 2008;11:97.
-
(2008)
Climacteric
, vol.11
, pp. 97
-
-
Simon, J.A.1
Komi, J.2
-
24
-
-
77952261120
-
Ospemifene improves the clinical signs of vaginal atrophy: Results from a pivotal phase 3 study [abstract P48]
-
Portman D, Komi J. Ospemifene improves the clinical signs of vaginal atrophy: results from a pivotal phase 3 study [abstract P48]. Menopause 2008;15:1222.
-
(2008)
Menopause
, vol.15
, pp. 1222
-
-
Portman, D.1
Komi, J.2
-
26
-
-
0033649898
-
Selective estrogen receptor modulators (SERMs) in clinical practice
-
Plouffe L Jr. Selective estrogen receptor modulators (SERMs) in clinical practice. J Soc Gynecol Investig 2000;7:S38-S46.
-
(2000)
J Soc Gynecol Investig
, vol.7
-
-
Plouffe L, Jr.1
|